telehealth prescriber asked me three questions and approved me. that is not care.
telehealth prescriber asked me three questions and approved me. that is not care — a position I have arrived at slowly and would like tested.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
If somebody has the same thing measured a different way, post it next to mine and we will see whether they agree.
best — the order this archive was captured in
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
potency testing on the finished preparation is the thing to ask for
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.
Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.